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http://dx.doi.org/10.1016/j.stemcr.2016.06.002SUMMARYConditional knockout mice are commonly used to study the function of specific genes in hematopoiesis. Different promoters that drive
Cre expression have been utilized, with the interferon-inducibleMx1-Cre still being the most commonly used ‘‘deleter strain’’ in exper-
imental hematology. However, different pitfalls associatedwith this system could lead tomisinterpretation in functional studies.We pre-
sent here two of these issues related to the use ofMx1-Cre: first, a high spontaneous recombination rate when applying commonly used
techniques in experimental hematology, and second, undesired short-term consequences of the use of polyinosinic:polycytidylic acid,
including changes in cellular phenotypes that, however, resolve within days. Our studies emphasize therefore that proper controls are
crucial when modeling gene deletion using the Mx1-Cre transgene.INTRODUCTION
Conditional knockout (cKO) mice based on Cre-mediated
excision (Jiang and Gridley, 1997) are frequently used
when studying normal and malignant hematopoiesis.
Most cKOmodels are generated by flanking a gene segment
of interest with loxP sites, which allows for its removal in
a cell- or tissue-specific manner by Cre recombinase. The
Mx1-Cre model (Kuhn et al., 1995) represents the most
commonly used ‘‘deleter strain’’ in experimental hematol-
ogy. In this strain, the Mx dynamin-like GTPase 1 (Mx1)
promoter is activated in an interferon-dependent manner
following injection of polyinosinic:polycytidylic acid
(pIpC), which results in downstream expression of Cre
recombinase. Despite the wide use of the Mx1-Cre strain,
caution has to be entertained due to caveats that have
not been well described. These include spontaneous
recombination and undesired side effects caused by the
pIpC itself.
In experimental hematology, bone marrow (BM) trans-
plantation represents a key approach in the investigation
of the role of specific genes. Most often, this is performed
with cells obtained from cKO mice. We show here that
the transplantation assay and expression of an activated re-
ceptor tyrosine kinase (FLT-3ITD) can trigger spontaneous
Mx1-Cre-driven deletion of floxed genes, which substan-
tially exceeded the 2%–3% originally reported (Kemp
et al., 2004; Kuhn et al., 1995; Mupo et al., 2013). In addi-
tion, we observed transient changes in phenotype and
frequency of hematopoietic stem and progenitor cells
(HSPCs) after pIpC injection, which could lead to incorrectSte
This is an open access article under the Cidentification of subsets of cells in short-term studies.
Finally, we propose a potential alternative strategy for
gene deletion using an ex vivo Tat-Cre-recombination
approach. Awareness of these shortcomings has high rele-
vance for hematopoietic research because it can aid in
experimental design and avoid potential errors in the inter-
pretation of results.RESULTS
Transplantation Induces Uncontrolled
Recombination in Hematopoietic Cells from
Mx1-CreMice
To study the influence of HIF-1a in the initiation of leuke-
mia, we retrovirally introduced different oncogenes into
Mx1-Cre; Hif-1aflox/flox cKIT+ cells and transplanted them
into wild-type (WT) recipients (Velasco-Hernandez et al.,
2014). Surprisingly, we observed an unexpectedly high
deletion frequency of the floxed gene prior to pIpC injec-
tion, ranging between 30% and 50% (Figure 1A).
To identify experimental procedures that contribute to
the spontaneous Mx1-Cre activation, we crossed Rosa26-
Lox-Stop-Lox-YFP (YFPLSL) reporter mice (Srinivas et al.,
2001) with the Mx1-Cre mice. HSPCs from these mice
were next subjected to a routine protocol for transduc-
tion/transplantation experiments, using retroviral vectors
encoding fluorescence proteins (Figures 1B–1G). Isolated
unmanipulated cells from donor mice displayed a sponta-
neous recombination close to 20% (Figures 1C, 1D, 1E,
1H, and S1). Analyses after transplantation indicated thatm Cell Reports j Vol. 7 j 11–18 j July 12, 2016 j ª 2016 The Author(s). 11
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Spontaneous Deletion of Floxed Genes in Hematopoietic Cells from Mx1-Cre Mice after Transplantation
(A) Frequency of HIF-1a-deleted colonies from peripheral blood cells derived from animals transplanted with transduced Mx1-Cre;
Hif-1aflox/flox HSPCs before (week 3 post-transplantation) and after pIpC injection (pIpC injection at week 4 and analysis at week 7). Plots
show two independent experiments, using either AML1-ETO9a or MLL-AF9 expressing donor cells.
(B) Experimental setup for analysis of spontaneous deletion in a commonly used transduction/transplantation protocol. Donor cells were
collected from five separate animals.
(C) Variation in frequency of recombined cells (YFP+) along the different steps of the protocol described in (B). Percentage of recombined
cells is calculated within the donor-derived population after the transplantation step. *p < 0.05.
(legend continued on next page)
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the percentage of YFP+ (recombined) cells in the donor-
derived compartment had increased significantly at week
10 (Figures 1C and S1). To address if this was due to the
transduction or transplantation procedures, we performed
the same protocol with or without transduction (Figures
1G and S1). Analysis of BM and spleen cells 15 days after
transplantation indicated that the levels of recombination
were similar in both groups. However, the frequency of re-
combined cells increased by 50% as a consequence of the
transplantation, despite the lack of an evident positive se-
lection pressure in favor of the recombined cells. Investiga-
tions into the effect of retroviral transduction in a more
primitive and homogeneous population (LinSCA1+cKIT+,
LSK cells) also failed to reveal increments in recombination
48 hr after transduction (Figures 1D and S2). Furthermore,
no significant increase in recombination was observed
when culturing unfractionated BM cells, including more
mature populations that could include interferon-produc-
ing cells (Figure 1E). Finally, to conclusively exclude a po-
tential positive selection of already recombined cells that
could increase in vivo after transplantation, we sorted
cKIT+ YFP cells from YFPLSL; Mx1-Cre mice and trans-
planted them into WT recipients without pIpC injection
(Figure 1H). This revealed 10%–20% of YFP+ donor cells
15 days after transplantation in donor BM and spleen cells
of transplanted mice.
These results demonstrate that the major cause of the
unexpectedly high levels of spontaneous gene deletion is
caused by the transplantation procedure per se.
Constitutively Active Flt-3 Induces Spontaneous
Recombination inMx1-CreMice
We recently crossed Hif-1a cKOmice with Flt-3ITD knockin
mice. We observed that a large fraction of hematopoietic
cells in these mice showed a spontaneous deletion prior
to pIpC injection ((Velasco-Hernandez et al., 2015) and Fig-
ure 2A), consistent with previous publications (Mead et al.,
2013; Mupo et al., 2013). To test if this was present also
early in development, we analyzed deletion in fetal liver
(FL) cells. FL hematopoietic cells showed either no deletion(D) Recombined cell frequency in YFPLSL; Mx1-Cre LSK cells at harvesti
(MIGR1): YFP+ cells from total cells (R1 population) and YFP+ cells w
were 10%–20%.
(E) Recombined cell frequency in unfractionated YFPLSL; Mx1-Cre BM
(F) Gating strategy used to analyze R1 and R2 population within tran
(G) Analysis of the effect of the transplantation alone on the sponta
directly transplanted or transduced with GFP virus before transplan
plantation (donor mice, n = 3; transplanted mice, n = 10). Recombi
independent donor. Transduction levels were between 10% and 50
**p < 0.01.
(H) Recombined cell frequency of donor-derived BM and spleen cells 1
(n = 4). Plots show mean ± SEM. TD, transduction. See also Figures Sor only a minor portion of deleted cells in a few colonies
(Figures 2A and S3), indicating that spontaneous Mx1-
Cre-mediated excision is a cumulative effect during the life-
span of these animals. Since it has been reported that
floxed alleles have different sensitivities to Cre-induced
recombination (Liu et al., 2013), we investigated sponta-
neous recombination in a different (Phd2flox/flox; Mx1-Cre;
Flt-3ITD/+) model. Using this, colonies derived from BM
cells were analyzed and consistently presented a high rate
of recombination in the absence of pIpC injection (Figures
2B and S3). Because FLT-3 signaling is critical for dendritic
cell (DC) differentiation and proliferation (Gilliet et al.,
2002; Karsunky et al., 2003; Maraskovsky et al., 1996;
O’Keeffe et al., 2002), and plasmacytoid DCs (pDCs) are
prominent producers of interferon (Colonna et al., 2004),
we analyzed BM and spleen in Flt-3ITD mice for pDCs
and classical DCs (cDCs) (Figures 2C, 2D, and S3). In
both organs, we observed increments in pDCs and cDCs
when comparing Flt-3ITD/+ withWTmice. These data imply
that spontaneous recombination can be induced by
FLT-3ITD expression, probably in an interferon-dependent
manner, illustrating that this phenomenon is not unique
to the transplantation system.
The Immunophenotype of HSPCs Is Transiently
Perturbed Following pIpC Administration
Interferon signaling has previously been shown to enhance
proliferation of HSPCs in vivo (Baldridge et al., 2010; Essers
et al., 2009). To evaluate this, we took advantage of an
in vivo approach in which a histone 2B-mCherry fusion
protein can be conditionally expressed in a doxycycline-
inducible manner (Sawen et al., 2016).
Col1a1-tetO-H2B-mCherrymicewere administered doxy-
cycline to label the pool of HSPCs, followed by assessments
of mCherry intensities in phenotypically defined subsets
at different time points (days 1, 3, 8, and 24) after pIpC
or PBS (control) injections. While proliferation of hemato-
poietic stem cells (HSCs, LinSCA1+cKIT+CD150+CD48)
was not appreciably altered at any time point after
pIpC injections (Figure 3A), lower mCherry intensitiesng/sorting time (day 0) or 48 hr after transduction with a GFP virus
ithin transduced cells (R2 population) (n = 4). Transduction levels
cells before and after 4 days culture (n = 4).
sduced cells.
neous recombination. YFPLSL; Mx1-Cre cKIT+ cells were isolated and
tation. Recombination levels were analyzed 15 days after trans-
nation levels are normalized to initial YFP+ cells values from each
%. Pooled data from two independent experiments. *p < 0.05,
5 days after transplantation with sorted YFPLSL; Mx1-Cre cKIT+ YFP
1 and S2.
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Figure 2. Spontaneous Deletion of
Different Floxed Genes in Hematopoietic
Cells fromMx1-CreMice Expressing Flt-3ITD
(A) Evaluation of Hif-1a deletion in colonies
derived from fetal liver (E14.5) (n = 4) or
BM (12-week-old mice) (n = 3) cells from
Flt-3ITD/+; Hif-1aflox/flox; Mx1-Cre embryos/
mice.
(B) Evaluation of Phd2 deletion in colonies
from BM (12-week-old mice) cells (n = 2)
from Flt-3ITD/+; Phd2flox/flox; Mx1-Cre mice.
(C and D) Flow cytometry analysis of den-
dritic cells (pDCs [CD45+CD19CD3CD11b
B220+ CD11clow/int] and cDCs [CD45+CD19
CD3CD11bB220CD11c+]) (C) in BM and
spleen (D) from FLT-3ITD/+ and WT animals
(n = 6). Plots show mean ± SEM. **p < 0.01,
***p < 0.001. See also Figure S3.suggested enhanced proliferation of granulocyte/macro-
phage lymphoid progenitors (GMLPs, LinSCA1+cKIT+
CD150CD48+) and more committed pre-granulocyte/
macrophageprogenitors (preGMs,LincKIT+SCA1CD150
CD105) in the short term (days 1 and 3) after pIpC
administration (Figure 3A). However, this effect was
not observed at later time points. While this potentially
could reflect an elimination of more rapidly proliferating
cells at later times, the frequencies of different HSPC
subsets (Figure S4) were dramatically altered early after
pIpC injections, but largely normalized after 3 days (Fig-
ures 3B and 3C). We noted transient elevations in the
levels of SCA1 1 day after pIpC injections, leading to
higher expression and frequency of SCA1+ cells (Fig-
ure 3D). This declined to levels observed in untreated
mice relatively rapidly. Therefore, pIpC doses typically
used for Cre induction do not cause any pronounced
effects on HSPC proliferation, but pIpC-mediated induc-
tion of SCA1 can complicate more refined phenotypic
analyses of these cells by ‘‘pushing’’ SCA1/low progeni-
tor cells into the pool of more primitive LSK cells. These
data highlight an additional and unwanted transient
effect of pIpC administration on hematopoiesis that14 Stem Cell Reports j Vol. 7 j 11–18 j July 12, 2016can lead to erroneous conclusions on cell identities in
short-term studies (before day 8).
An Alternative In Vitro Cre-Recombination Strategy
Using Ex Vivo Tat-Cre Treatment
Finally, to explore an alternative approach to the Mx1-
Cre-mediated recombination, we subjected HSPCs from
Rosa26-LoxP-Stop-LoxP-RFP(TdTomato) (TdTomatoLSL)
mice to a brief in vitro exposure to recombinant Tat-
Cre. This revealed an efficient induction of RFP expres-
sion, with no spontaneous deletion in the absence of
Tat-Cre (Figures 4A and 4B). We next applied this dele-
tion strategy to investigate the impact of an activating
KRASG12D mutation onMLL-ENL-driven leukemia in vivo.
This KRASG12D model has previously been shown to asso-
ciate with a relatively high level of spontaneous activa-
tion when crossed to Mx1-Cre mice (Chan et al., 2004;
Sabnis et al., 2009). After crossing doxycycline-inducible
MLL-ENL mice (Ugale et al., 2014) to the KRASLSLG12D
strain, we sorted HSCs and subjected these to Tat-Cre or
sham recombination, followed by transplantation. As ex-
pected (Ugale et al., 2014), recipients of HSCs expressing
only the MLL-ENL oncogene (no Tat-Cre) failed to
A B
C
D
Figure 3. Alterations in Phenotype of BM
Stem and Progenitor Subsets after pIpC
Injections
(A) Col1a1-tetO-H2B-mCherry mice fed with
doxycycline-containing food were injected
with pIpC and analyzed 1 (n = 4), 3 (n = 4), 8
(n = 3), and 24 days (n = 3) after the last
injection. Representative histograms show
H2B-mCherry label retention in HSPCs at the
indicated time points after pIpC injection.
(B and C) Frequencies of (B) phenotypic
myeloid progenitors and (C) LSK HSPC
subsets 24 or 72 hr following one pIpC
injection.
(D) SCA1 expression in phenotypically
defined HSCs and GMLPs. In red, mean fluo-
rescent intensity (MFI) values of SCA1 and,
in blue, average percentage of SCA1+ cells
(blue gating). Plots represent mean ± SD.
Ctrl, control; HSC, hematopoietic stem cell;
GMLP, granulocyte/macrophage lymphoid
progenitors; preGM, pre-granulocyte/macro-
phage progenitors; MkP, megakaryocyte
progenitor; preMegE, pre-megakaryocyte–erythrocyte progenitors; preCFU-E, pre-colony-forming units-erythrocytes; CFU-E, colony-
forming units-erythrocytes; MPP, multipotent progenitor; LSK, LinSCA1+cKIT+. See also Figure S4.develop leukemia, while all recipients with combined
activation of KRASG12D and MLL-ENL (+ Tat-Cre) devel-
oped myeloid leukemia within 10 weeks (Figure 4C).
To test this strategy in a non-leukemic model in which
recombined cells have no selective advantage, we isolated
LSK cells from the YFPLSL model (lacking Mx1-Cre) and
applied the same protocol (Figures 4D and 4E). We
observed recombination rates of 2%–8%, also present
in BM and spleen cells 15 days after transplantation.
We did not observe any undesired recombination in
sham-recombined cells. These results demonstrate the
utility of an alternative recombination strategy that can
circumvent some of the technical caveats associated
with the Mx1-Cre system, although we have not rigor-
ously shown that recombination occurs in stem cells
with this system.DISCUSSION
In experimental hematopoiesis, the requirement of specific
genes for normal HSC function, initiation, and mainte-
nance of leukemia, using either transplantation alone
or the retroviral transduction/transplantation model, has
been tested extensively using specific cKO mice (Kocabas
et al., 2012; Takeishi et al., 2013; Wang et al., 2010; Zhang
et al., 2004). However, the requirement of a specific gene
for leukemia initiation will be difficult to evaluate if the
gene to be tested is deleted in an uncontrolled manner.It is a general assumption that deletion of floxed genes
using the Mx1-Cre system occurs by pIpC injections either
in steady-state hematopoiesis or after engraftment into re-
cipients. Yet, despite its widespread use, little information
is available on baseline levels of recombination and the in-
fluence of transplantation itself on spontaneous gene dele-
tion. When we investigated the role of HIF-1a in leukemia
initiation by transducing HSPCs from Hif-1a cKO mice
with leukemic oncogenes, we observed a 40% gene dele-
tion frequency after transplantation, but prior to pIpC
injections. This led us to further investigate this phenome-
non because of its broader importance for hematopoi-
esis and leukemia research, in which these methods are
commonly used.
In the literature, a spontaneous recombination rate of
2%–3% when using the Mx1-Cre deleter strain has been
described (Kemp et al., 2004; Kuhn et al., 1995; Mupo
et al., 2013). Even a low recombination rate can lead to a
high gene deletion frequency if the cells with the deleted
gene have a growth advantage; for example, when investi-
gating leukemia initiation. Based on our findings,Mx1-Cre
mice not injected with pIpC should be included in all ex-
periments using this model and deletion assessed before
initiation of experiments. This is not unique to the trans-
plantation scenario, as we observed that activation of
Mx1-Cre can also be triggered by an oncogene (constitutive
active Flt-3). Activation of this pathway, which leads to
excessive generation and activation of interferon-produc-
ing DCs, is likely induced also by other activated receptorStem Cell Reports j Vol. 7 j 11–18 j July 12, 2016 15
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Figure 4. Alternative Strategy for Cre-
Mediated Excision Using Ex Vivo Treat-
ment with Tat-Cre Recombinase
(A) Schematic outline of the in vitro Cre-
recombination alternative strategy using
Tat-Cre recombinase.
(B) TdTomatoLSL HSCs were treated with
Tat-Cre in vitro. Representative fluores-
cence-activated cell sorting (FACS) plots of
TdTomato expression in cells after 3 days in
culture are shown.
(C) Col1a1-tetO-MLL/ENL x KRASLSLG12D
HSCs were induced in vitro with Tat-Cre to
promote the activation of KRASG12D. Kaplan-
Meier curves depict the survival of mice
transplanted with Tat-Cre-induced (n = 6) or
uninduced (n = 7) HSCs, under continuous
MLL-ENL activation with doxycycline-con-
taining food. ***p < 0.001.
(D) YFP expression in BM and spleen of
transplanted mice with YFPLSL LSK cells, Tat-
Cre or sham treated, 15 days after trans-
plantation (donor mice, n = 3; transplanted
mice, n = 5).
(E) Representative FACS plots of YFP expres-
sion in donor BM cells.
(F) YFP expression in LSK and cKIT+ cells in
the transplanted mice shown in (D).
Plots show means ± SEM.tyrosine kinases, and might therefore be particularly prob-
lematic in combination with the Mx1-Cre system.
The Mx1-Cre system can be potentially associated with
additional problems. For instance, pIpC administration
has been suggested to trigger HSC cycling, similar to inter-
feron itself (Essers et al., 2009; Gidali et al., 1981; Sugiyama
et al., 2006). While we found less evidence for a dramatic
effect of pIpC in inducing HSPC proliferation, we noted
that pIpC induced rapid and transient changes (that
resolved by day 8) in cellular phenotypes, which could
affect the interpretation of experimental results.
Several alternatives to theMx1-Cremodel can be found in
the literature (Joseph et al., 2013; Kemp et al., 2004; Lewan-
doski, 2001; Rossi et al., 2012). In addition, we provide ev-
idence for the use of Tat-Cre recombinase (Peitz et al., 2002)
as an alternative method (De Santa et al., 2007; Gordon16 Stem Cell Reports j Vol. 7 j 11–18 j July 12, 2016et al., 2012; Li et al., 2014). Because Tat-Cre-mediated exci-
sion represents an exogenous expression system, cells are
not susceptible to undesired recombination. However,
this method also has limitations since it relies on an
ex vivo step for the treatment with Tat-Cre, and is therefore
not compatible with steady-state studies or for the study of
genes necessary for homing. In addition, we have observed
a significant variation in the recombination rate depend-
ing on the floxed gene, as described previously for Cre
strains in general (Liu et al., 2013). Although the data we
report herein displayed a rather low recombination rate,
deletion efficiencies can be substantially increased in a
cell-type-dependent and procedure-specific manner (data
not shown). However, it is perhaps unlikely that the proce-
dure will be able to reach 100% efficiencies. The titratable
recombination rates can, however, also be beneficial, for
instance in leukemogenesis studies, in which only a small
percentage of recombined cells is desired.
In summary, we present evidence from multiple experi-
mental conditions and procedures that can contribute
to the induction of high spontaneous recombination in
Mx1-Cre-based cKO mice. Being up to 20-fold higher than
the ones reported in the literature for steady-state condi-
tions, our studies highlight the importance of proper con-
trols when applying this system to study gene function in
the hematopoietic system.EXPERIMENTAL PROCEDURES
Mice
The following mouse strains were used: Flt-3ITD (Lee et al., 2007)
(kindly provided by G. Gilliland), Mx1-Cre (Kuhn et al., 1995),
Hif-1aflox/flox (Ryan et al., 2000), Phd2flox/flox (kindly provided by
P. Carmeliet), YFPLSL (Srinivas et al., 2001) (JAX 006148), Col1a1-
tetO-H2B-mCherry (Egli et al., 2007) (JAX 014602), TdTomatoLSL
(Madisen et al., 2010) (JAX 007905), Col1a1-tetO-MLL/ENL (Ugale
et al., 2014), and KRASLSL-G12D (Jackson et al., 2001) (JAX 008179).
To activate Mx1-Cre in vivo, 400 mg of pIpC (Sigma-Aldrich) was
either injected three times every second day or once (analyzed
samples at days 1 and 3). Mice were maintained at the animal
facilities of the Biomedical Center at Lund University. All ex-
periments were performed with consent from a local ethics
committee.
Statistical Analysis
Data were analyzed using Microsoft Excel (Microsoft) and Prism 6
(GraphPad Software). Data are expressed as means ± SEM or SD.
‘‘n’’ always stands for individual mice. Differences between groups
were assessed by two-tailed Student’s t test. Survival rates were
plotted using the Kaplan-Meier method (significance values were
calculated by Mantel-Cox log rank test). *p < 0.05, **p < 0.01,
***p < 0.001.
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Procedures and four figures and can be found with this article on-
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AUTHOR CONTRIBUTIONS
T.V. and P.S. performed the experiments, analyzed the data, and
generated the figures. T.V., P.S., D.B., and J.C. designed the experi-
ments and wrote the paper.
ACKNOWLEDGMENTS
We would like to thank Gary Gilliland (Fred Hutchinson Cancer
Center, Seattle, USA) and Peter Carmeliet (Flanders Institute for
Biotechnology, VIB, KU Leuven, Belgium) for kindly providing
Flt-3ITD and Phd2flox/floxmice, respectively. This studywas financed
by a post-doctoral fellowship grant and a project grant by Barncan-
cerfonden to T.V. and J.C., respectively. Additional financing wasprovided by ERC consolidator grant 615068 to D.B. and the Hem-
ato-Linne grant from Vetenskapsra˚det to D.B. and J.C.
Received: August 10, 2015
Revised: June 3, 2016
Accepted: June 3, 2016
Published: June 30, 2016REFERENCES
Baldridge, M.T., King, K.Y., Boles, N.C., Weksberg, D.C., and
Goodell, M.A. (2010). Quiescent haematopoietic stem cells are
activated by IFN-gamma in response to chronic infection. Nature
465, 793–797.
Chan, I.T., Kutok, J.L., Williams, I.R., Cohen, S., Kelly, L., Shige-
matsu, H., Johnson, L., Akashi, K., Tuveson, D.A., Jacks, T., et al.
(2004). Conditional expression of oncogenic K-ras from its endog-
enous promoter induces a myeloproliferative disease. J. Clin.
Invest. 113, 528–538.
Colonna,M., Trinchieri, G., and Liu, Y.J. (2004). Plasmacytoid den-
dritic cells in immunity. Nat. Immunol. 5, 1219–1226.
De Santa, F., Totaro,M.G., Prosperini, E., Notarbartolo, S., Testa, G.,
and Natoli, G. (2007). The histone H3 lysine-27 demethylase
Jmjd3 links inflammation to inhibition of polycomb-mediated
gene silencing. Cell 130, 1083–1094.
Egli, D., Rosains, J., Birkhoff, G., and Eggan, K. (2007). Develop-
mental reprogramming after chromosome transfer into mitotic
mouse zygotes. Nature 447, 679–685.
Essers, M.A., Offner, S., Blanco-Bose, W.E., Waibler, Z., Kalinke, U.,
Duchosal, M.A., and Trumpp, A. (2009). IFNalpha activates
dormant haematopoietic stem cells in vivo. Nature 458, 904–908.
Gidali, J., Feher, I., and Talas, M. (1981). Proliferation inhibition of
murine pluripotent haemopoietic stem cells by interferon or poly
I:C. Cell Tissue Kinet. 14, 1–7.
Gilliet, M., Boonstra, A., Paturel, C., Antonenko, S., Xu, X.L., Trin-
chieri, G., O’Garra, A., and Liu, Y.J. (2002). The development of
murine plasmacytoid dendritic cell precursors is differentially
regulated by FLT3-ligand and granulocyte/macrophage colony-
stimulating factor. J. Exp. Med. 195, 953–958.
Gordon, S.M., Chaix, J., Rupp, L.J., Wu, J., Madera, S., Sun, J.C.,
Lindsten, T., and Reiner, S.L. (2012). The transcription factors
T-bet and Eomes control key checkpoints of natural killer cell
maturation. Immunity 36, 55–67.
Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D.,
Montoya, R., Jacks, T., and Tuveson, D.A. (2001). Analysis of
lung tumor initiation and progression using conditional expres-
sion of oncogenic K-ras. Genes Dev. 15, 3243–3248.
Jiang, R., and Gridley, T. (1997). Gene targeting: things go better
with Cre. Curr. Biol. 7, R321–R323.
Joseph, C., Quach, J.M.,Walkley, C.R., Lane, S.W., LoCelso, C., and
Purton, L.E. (2013). Deciphering hematopoietic stem cells in their
niches: a critical appraisal of genetic models, lineage tracing, and
imaging strategies. Cell Stem Cell 13, 520–533.
Karsunky, H., Merad, M., Cozzio, A., Weissman, I.L., and Manz,
M.G. (2003). Flt3 ligand regulates dendritic cell developmentStem Cell Reports j Vol. 7 j 11–18 j July 12, 2016 17
from Flt3+ lymphoid andmyeloid-committed progenitors to Flt3+
dendritic cells in vivo. J. Exp. Med. 198, 305–313.
Kemp, R., Ireland, H., Clayton, E., Houghton, C., Howard, L., and
Winton, D.J. (2004). Elimination of background recombination:
somatic induction of Cre by combined transcriptional regulation
and hormone binding affinity. Nucleic Acids Res. 32, e92.
Kocabas, F., Zheng, J., Thet, S., Copeland, N.G., Jenkins, N.A., De-
Berardinis, R.J., Zhang, C., and Sadek, H.A. (2012). Meis1 regulates
the metabolic phenotype and oxidant defense of hematopoietic
stem cells. Blood 120, 4963–4972.
Kuhn, R., Schwenk, F., Aguet, M., and Rajewsky, K. (1995). Induc-
ible gene targeting in mice. Science 269, 1427–1429.
Lee, B.H., Tothova, Z., Levine, R.L., Anderson, K., Buza-Vidas, N.,
Cullen, D.E., McDowell, E.P., Adelsperger, J., Frohling, S., Huntly,
B.J., et al. (2007). FLT3 mutations confer enhanced proliferation
and survival properties to multipotent progenitors in a murine
model of chronic myelomonocytic leukemia. Cancer Cell 12,
367–380.
Lewandoski, M. (2001). Conditional control of gene expression in
the mouse. Nat. Rev. Genet. 2, 743–755.
Li, Y.F., Xu, S., Ou, X., and Lam, K.P. (2014). Shp1 signalling is
required to establish the long-lived bone marrow plasma cell
pool. Nat. Commun. 5, 4273.
Liu, J., Willet, S.G., Bankaitis, E.D., Xu, Y., Wright, C.V., and Gu, G.
(2013). Non-parallel recombination limits Cre-LoxP-based re-
porters as precise indicators of conditional genetic manipulation.
Genesis 51, 436–442.
Madisen, L., Zwingman, T.A., Sunkin, S.M., Oh, S.W., Zariwala,
H.A., Gu, H., Ng, L.L., Palmiter, R.D., Hawrylycz, M.J., Jones,
A.R., et al. (2010). A robust and high-throughput Cre reporting
and characterization system for the whole mouse brain. Nat. Neu-
rosci. 13, 133–140.
Maraskovsky, E., Brasel, K., Teepe, M., Roux, E.R., Lyman, S.D.,
Shortman, K., and McKenna, H.J. (1996). Dramatic increase in
the numbers of functionally mature dendritic cells in Flt3 ligand-
treated mice: multiple dendritic cell subpopulations identified.
J. Exp. Med. 184, 1953–1962.
Mead, A.J., Kharazi, S., Atkinson, D., Macaulay, I., Pecquet, C.,
Loughran, S., Lutteropp, M., Woll, P., Chowdhury, O., Luc, S.,
et al. (2013). FLT3-ITDs instruct a myeloid differentiation and
transformation bias in lymphomyeloid multipotent progenitors.
Cell Rep. 3, 1766–1776.
Mupo, A., Celani, L., Dovey, O., Cooper, J.L., Grove, C., Rad, R.,
Sportoletti, P., Falini, B., Bradley, A., and Vassiliou, G.S. (2013).
A powerful molecular synergy between mutant Nucleophosmin
and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia
27, 1917–1920.
O’Keeffe, M., Hochrein, H., Vremec, D., Pooley, J., Evans, R.,
Woulfe, S., and Shortman, K. (2002). Effects of administration of
progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating
factor, and pegylated granulocyte-macrophage colony-stimulating
factor on dendritic cell subsets in mice. Blood 99, 2122–2130.18 Stem Cell Reports j Vol. 7 j 11–18 j July 12, 2016Peitz, M., Pfannkuche, K., Rajewsky, K., and Edenhofer, F. (2002).
Ability of the hydrophobic FGF and basic TAT peptides to promote
cellular uptake of recombinant Cre recombinase: a tool for efficient
genetic engineering of mammalian genomes. Proc. Natl. Acad. Sci.
USA 99, 4489–4494.
Rossi, L., Lin, K.K., Boles, N.C., Yang, L., King, K.Y., Jeong, M.,
Mayle, A., and Goodell, M.A. (2012). Less is more: unveiling the
functional core of hematopoietic stem cells through knockout
mice. Cell Stem Cell 11, 302–317.
Ryan, H.E., Poloni, M., McNulty, W., Elson, D., Gassmann, M., Ar-
beit, J.M., and Johnson, R.S. (2000). Hypoxia-inducible factor-
1alpha is a positive factor in solid tumor growth. Cancer Res. 60,
4010–4015.
Sabnis, A.J., Cheung, L.S., Dail, M., Kang, H.C., Santaguida, M.,
Hermiston, M.L., Passegue, E., Shannon, K., and Braun, B.S.
(2009). Oncogenic Kras initiates leukemia in hematopoietic stem
cells. PLoS Biol. 7, e59.
Sawen, P., Lang, S., Mandal, P., Rossi, D.J., Soneji, S., and Bryder, D.
(2016). Mitotic history reveals distinct stem cell populations and
their contributions to hematopoiesis. Cell Rep. 14, 2809–2818.
Srinivas, S., Watanabe, T., Lin, C.S., William, C.M., Tanabe, Y., Jes-
sell, T.M., and Costantini, F. (2001). Cre reporter strains produced
by targeted insertion of EYFP and ECFP into the ROSA26 locus.
BMC Dev. Biol. 1, 4.
Sugiyama, T., Kohara, H., Noda, M., and Nagasawa, T. (2006).
Maintenance of the hematopoietic stem cell pool by CXCL12-
CXCR4 chemokine signaling in bone marrow stromal cell niches.
Immunity 25, 977–988.
Takeishi, S., Matsumoto, A., Onoyama, I., Naka, K., Hirao, A., and
Nakayama, K.I. (2013). Ablation of Fbxw7 eliminates leukemia-
initiating cells by preventing quiescence. Cancer Cell 23, 347–361.
Ugale, A., Norddahl, G.L., Wahlestedt, M., Sawen, P., Jaako, P.,
Pronk, C.J., Soneji, S., Cammenga, J., and Bryder, D. (2014).
Hematopoietic stem cells are intrinsically protected against
MLL-ENL-mediated transformation. Cell Rep. 9, 1246–1255.
Velasco-Hernandez, T., Hyrenius-Wittsten, A., Rehn, M., Bryder,
D., and Cammenga, J. (2014). HIF-1alpha can act as a tumor
suppressor gene in murine acute myeloid leukemia. Blood 124,
3597–3607.
Velasco-Hernandez, T., Tornero, D., andCammenga, J. (2015). Loss
of HIF-1alpha acceleratesmurine FLT-3ITD-inducedmyeloprolifer-
ative neoplasia. Leukemia 29, 2366–2374.
Wang, Y., Krivtsov, A.V., Sinha, A.U., North, T.E., Goessling, W.,
Feng, Z., Zon, L.I., and Armstrong, S.A. (2010). The Wnt/beta-cat-
enin pathway is required for the development of leukemia stem
cells in AML. Science 327, 1650–1653.
Zhang, P., Iwasaki-Arai, J., Iwasaki, H., Fenyus, M.L., Dayaram, T.,
Owens, B.M., Shigematsu, H., Levantini, E., Huettner, C.S., Lek-
strom-Himes, J.A., et al. (2004). Enhancement of hematopoietic
stem cell repopulating capacity and self-renewal in the absence
of the transcription factor C/EBP alpha. Immunity 21, 853–863.
